Luigi Messori

Luigi Messori's AcademicInfluence.com Rankings

Luigi Messori

Physics

#7505

World Rank

#9539

Historical Rank

physics Degrees

Download Badge

Physics

Luigi Messori's Degrees

PhD Physics University of Bologna
Masters Physics University of Bologna
Bachelors Physics University of Bologna

Why Is Luigi Messori Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luigi Messori's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs (2009) (453)
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies (2010) (374)
Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. (2000) (295)
Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. (2004) (260)
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. (2008) (246)
Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. (2008) (226)
Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. (2002) (223)
Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. (2004) (181)
Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. (2010) (179)
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry (2019) (175)
Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. (2006) (165)
The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. (1994) (165)
Molecular mechanisms and proposed targets for selected anticancer gold compounds. (2011) (153)
New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications (2008) (147)
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. (2007) (141)
Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity. (2011) (134)
Metal Ion Physiopathology in Neurodegenerative Disorders (2009) (128)
A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition (2011) (127)
Challenges associated with metal chelation therapy in Alzheimer's disease. (2009) (124)
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study (2009) (121)
Cisplatin binding to proteins: A structural perspective (2016) (117)
Gold(III) compounds as anticancer drugs (2007) (115)
A comparative study of aluminum(III), gallium(III), indium(III), and thallium(III) binding to human serum transferrin (2002) (112)
A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin. (2000) (111)
Mechanisms of cytotoxicity of selected organogold(III) compounds. (2005) (111)
Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. (1999) (111)
Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. (2009) (103)
DNA as a possible target for antitumor ruthenium(III) complexes. (2000) (101)
Structural investigation of cisplatin-protein interactions: selective platination of His19 in a cuprozinc superoxide dismutase. (2006) (96)
Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. (2008) (95)
Formation of Supramolecular Structures between DNA and Starburst Dendrimers Studied by EPR, CD, UV, and Melting Profiles (2000) (93)
Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound (2009) (91)
Cisplatin binding to human serum albumin: a structural study. (2015) (90)
Interactions of selected gold(III) complexes with calf thymus DNA. (2001) (88)
Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c (2006) (83)
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin (2003) (82)
Gold complexes in the treatment of rheumatoid arthritis. (2004) (81)
Use of Hydrophobic Ligands for the Stabilization of Low-Valent Transition Metal Complexes. 1. The Effect of N-Methylation of Linear Tetraazaalkane Ligands on the Properties of Their Copper Complexes (1995) (81)
Chelation therapy for neurodegenerative diseases (2009) (80)
Reactions of gold(III) complexes with serum albumin. (2003) (79)
Thioredoxin reductase, an emerging target for anticancer metallodrugs (2011) (79)
Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI (2007) (78)
A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. (2004) (78)
Antimalarial properties of green tea. (2007) (78)
Potential pathogenic role of β-amyloid1–42–aluminum complex in Alzheimer's disease ☆ (2008) (78)
ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)‐Arene PTA (RAPTA) Complexes (2007) (77)
Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. (2016) (75)
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers (2003) (75)
Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment (2005) (73)
Trace copper(II) or zinc(II) ions drastically modify the aggregation behavior of amyloid-beta1-42: an AFM study. (2010) (73)
INVESTIGATION OF CU2CO2SOD AND ITS ANION DERIVATIVES. PROTON NMR AND ELECTRONIC SPECTRA (1985) (73)
Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichloro(o-phenanthroline)gold(III) chloride (2000) (72)
Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives. (2012) (72)
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. (2010) (71)
Identification of the iron ions of high potential iron protein from Chromatium vinosum within the protein frame through two-dimensional NMR experiments (1992) (71)
Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents. (2014) (70)
[Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties. (2010) (70)
A BINOL-based chiral polyammonium receptor for highly enantioselective recognition and fluorescence sensing of (S,S)-tartaric acid in aqueous solution. (2012) (70)
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. (2017) (68)
The mode of action of anticancer gold-based drugs: a structural perspective. (2013) (67)
Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies. (2008) (66)
fac-{Ru(CO)(3)}(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes. (2010) (66)
Coordination modes of histidine. 10. Iron(III) tyrosinate models. Synthesis and spectroscopic and stereochemical studies of iron(III) complexes of N-salicylidene-L-amino acids (1987) (66)
The reaction of artemisinins with hemoglobin: a unified picture. (2006) (64)
Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) N-Heterocyclic Carbene Complexes. (2016) (63)
Simple and rapid physico-chemical methods to examine action of antimalarial drugs with hemin: its application to Artemisia annua constituents. (2002) (62)
Solution chemistry and cytotoxic properties of novel organogold(III) compounds. (2004) (62)
The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. (2003) (61)
Protein Metalation by Anticancer Metallodrugs: A Joint ESI MS and XRD Investigative Strategy. (2017) (60)
Decomposition of ascorbic acid in the presence of cadmium ions leads to formation of a polymeric cadmium oxalate species with peculiar structural features. (2002) (58)
Metal compounds as inhibitors of β-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease (2012) (58)
Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation. (2014) (58)
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study (2010) (57)
Cisplatin binding to proteins: molecular structure of the ribonuclease a adduct. (2014) (55)
Gold(III) Compounds as New Family of Anticancer Drugs (2003) (54)
Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. (2009) (54)
Modeling of copper(II) sites in proteins based on histidyl and glycyl residues. (2003) (53)
Gold(III) compounds as potential antitumor agents: Cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes (1998) (53)
Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections (2014) (53)
Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. (2008) (52)
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm). (1997) (52)
Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme. (2014) (51)
Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. (2013) (50)
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. (2010) (50)
Gold complexes as antitumor agents. (2004) (48)
Speciation of metal-based nanomaterials in human serum characterized by capillary electrophoresis coupled to ICP-MS: a case study of gold nanoparticles. (2015) (48)
Promising in Vitro anti-Alzheimer Properties for a Ruthenium(III) Complex. (2013) (48)
Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA. (2001) (48)
Cisplatin encapsulation within a ferritin nanocage: a high-resolution crystallographic study. (2016) (48)
Unravelling the chemical nature of copper cuprizone. (2007) (48)
Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins (2000) (47)
Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin. (2008) (47)
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. (2019) (47)
Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes (1999) (47)
Recent progress in the application of analytical techniques to anticancer metallodrug proteomics (2011) (47)
Spectroscopic and potentiometric study of the SOD mimic system copper(II)/acetyl-L-histidylglycyl-L-histidylglycine. (2002) (47)
The Interaction of the Antitumor Complexes Na[trans-RuCl4 (DMSO)(Im)] and Na[trans-RuCl4(DMSO)(Ind)] With Apotransferrin: a Spectroscopic Study (1996) (47)
Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. (2007) (46)
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). (2000) (46)
New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. (2010) (46)
Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line (1996) (45)
1H-NMR studies on partially and fully reduced 2(4Fe-4S) ferredoxin from Clostridium pasteurianum. (1992) (45)
Unusual structural features in the lysozyme derivative of the tetrakis(acetato)chloridodiruthenium(II,III) complex. (2014) (45)
Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c (2007) (44)
2D 1H NMR studies of oxidized 2(Fe4S4) ferredoxin from Clostridium pasteurianum (1991) (43)
The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells (2017) (43)
Protein-binding Properties of two Antitumour Ru(III) Complexes to Human Apotransferrin and Apolactoferrin (1994) (43)
Size dependent biological profiles of PEGylated gold nanorods. (2014) (43)
Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. (2007) (42)
Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies. (2017) (42)
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. (2003) (42)
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme (2012) (41)
Proton NMR studies of the cobalt(II)-metallothionein system (1989) (40)
Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A. (2004) (40)
Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme. (2015) (40)
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study (2018) (40)
Interactions of gold-based drugs with proteins: crystal structure of the adduct formed between ribonuclease A and a cytotoxic gold(III) compound. (2014) (39)
Auranofin and its Analogues Show Potent Antimicrobial Activity against Multidrug‐Resistant Pathogens: Structure–Activity Relationships (2018) (39)
Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents. (2015) (39)
cis-Pt I2(NH3)2: a reappraisal. (2015) (38)
Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. (2011) (38)
Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. (2012) (38)
Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems. (2015) (38)
Exploring the reactions of β-amyloid (Aβ) peptide 1-28 with Al(III) and Fe(III) ions. (2011) (37)
ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. (2020) (37)
The X‐ray Structure of the Adduct between NAMI‐A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins (2010) (37)
Solution NMR Structure of a Ligand/Hybrid-2-G-Quadruplex Complex Reveals Rearrangements that Affect Ligand Binding. (2017) (37)
Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. (2008) (36)
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. (2013) (36)
The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme. (2014) (35)
fac-{Ru(CO)3}2+-core complexes and design of metal-based drugs. synthesis, structure, and reactivity of Ru-thiazole derivative with serum proteins and absorption-release studies with acryloyl and silica hydrogels as carriers in physiological media. (2007) (35)
Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS. (2018) (35)
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties. (2012) (34)
Synthesis, molecular structure and solution chemistry of the iridium(III) complex imidazolium [trans(bisimidazole)tetrachloro iridate(III)] (IRIM) (2001) (34)
Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity. (2001) (34)
Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs (2020) (34)
Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents. (2003) (34)
A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin (2020) (34)
The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif. (2007) (34)
NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. (2014) (33)
Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytotoxic gold(III) compound Auoxo3. (2014) (33)
Structure and DNA binding properties of the gold(III) complex (AuCl2(esal)) (1999) (33)
Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. (2010) (33)
Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts. (2015) (33)
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c). (2014) (33)
Reactivity and biological properties of a series of cytotoxic PtI2(amine)2 complexes, either cis or trans configured. (2012) (33)
Selection and characterization of a human ovarian cancer cell line resistant to auranofin (2017) (33)
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. (1998) (33)
Tl as an NMR probe for the investigation of transferrin (1983) (32)
Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent. (2019) (32)
DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques. (2007) (32)
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. (2016) (32)
Metal‐Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes (2013) (31)
Spectral characterization of ruthenium (III) transferrin. (1993) (31)
Peculiar mechanistic and structural features of the carboplatin–cytochrome c system revealed by ESI-MS analysis (2008) (31)
Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding. (2015) (31)
Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(I)-NHC complex. (2015) (31)
The copper(II) binding properties of the cyclic peptide c(HGHK). (2004) (31)
Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. (2014) (30)
Investigation of the effects of copper ions on protein aggregation using a model system (2004) (30)
Molecular Recognition of Metal Complexes by DNA: A Comparative Study of the Interactions of the Parent Complexes [PtCl(TERPY)]Cl and [AuCl(TERPY)]Cl 2 with Double Stranded DNA (2005) (30)
Structural features of a new dinuclear platinum(II) complex with significant antiproliferative activity. (2003) (30)
PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. (2017) (30)
The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years? (2018) (29)
Protein targets for anticancer gold compounds: mechanistic inferences. (2011) (29)
Rapid purification of gold nanorods for biomedical applications (2014) (29)
Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. (2009) (29)
Carbon-13 NMR study of the synergistic anion in transferrins (1986) (29)
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. (2012) (29)
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. (2011) (29)
Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex. (2010) (28)
The X-ray structure of the primary adducts formed in the reaction between cisplatin and cytochrome c. (2015) (28)
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. (2012) (27)
A first-in-class and a fished out anticancer platinum compound: cis-[PtCl2(NH3)2] and cis-[PtI2(NH3)2] compared for their reactivity towards DNA model systems. (2016) (27)
Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c.). (2014) (27)
Impact of ring size on the copper(II) coordination abilities of cyclic tetrapeptides. (2009) (26)
Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) (2009) (26)
Gold(III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies. (2015) (26)
Gold(III) complexes as a new family of cytotoxic and antitumor agents (2002) (26)
X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins (2011) (26)
Butyltin(IV) Benzoates: Inhibition of Thioredoxin Reductase, Tumor Cell Growth Inhibition, and Interactions with Proteins (2013) (26)
Structure-function relationships within Keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)]. (2005) (25)
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. (2017) (25)
Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. (2011) (25)
Cisplatin Binding Sites in Human H-Chain Ferritin. (2017) (24)
A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies (2018) (24)
Interactions between anticancer trans-platinum compounds and proteins: crystal structures and ESI-MS spectra of two protein adducts of trans-(dimethylamino)(methylamino)dichloridoplatinum(II). (2014) (24)
The cisplatin/serum albumin system: A reappraisal (2019) (24)
Metal-induced conformational heterogeneity of transferrins: a spectroscopic study of indium(III) and other metal(III)-substituted transferrins. (1995) (23)
Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study (2020) (23)
Ru-Based CO releasing molecules with azole ligands: interaction with proteins and the CO release mechanism disclosed by X-ray crystallography. (2017) (23)
New gold carbene complexes as candidate anticancer agents (2016) (23)
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen. (2007) (23)
Solution studies of the antitumor complex dichloro 1,2-propylendiaminetetraacetate ruthenium (III) and of its interactions with proteins. (1998) (22)
Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxicam complexes. In vivo evaluation of anti-inflammatory and gastric damaging activities. (2014) (22)
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents (2012) (21)
Interaction of a gold(i) dicarbene anticancer drug with human telomeric DNA G-quadruplex: solution and computationally aided X-ray diffraction analysis. (2018) (21)
Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. (2014) (21)
Reactions of Medicinal Gold(III) Compounds With Proteins and Peptides Explored by Electrospray Ionization Mass Spectrometry and Complementary Biophysical Methods (2020) (21)
Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. (2016) (21)
Structure of a terbium(III)-quinizarine complex: the first crystallographic model for metalloanthracyclines. (2003) (21)
1H NMR spectroscopic characterization of binary and ternary complexes of cobalt(II) carboxypeptidase A with inhibitors. (1988) (20)
Structural effects of titanium citrate on the human erythrocyte membrane. (2005) (20)
The C2 variant of human serum transferrin retains the iron binding properties of the native protein. (2005) (20)
Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. (2016) (19)
Structural Characterization of a Gold/Serum Albumin Complex. (2019) (19)
Kinetic studies on metal removal from transferrins by pyrophosphate. Investigation on iron(III) and manganese(III) derivatives (1988) (19)
{Ru(CO)x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. (2017) (19)
Solution chemistry and DNA binding properties of MEN 10755, a novel disaccharide analogue of doxorubicin. (2001) (19)
A theoretical analysis of the 1H nuclear magnetic relaxation dispersion profiles of diferric transferrin (1995) (19)
The disaccharide anthracycline MEN 10755 binds human serum albumin to a non-classical drug binding site. (2002) (18)
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents (2017) (18)
Spectrophotometric and ESI-MS/HPLC studies reveal a common mechanism for the reaction of various artemisinin analogues with hemin. (2003) (17)
The NAMI A - human ferritin system: a biophysical characterization. (2018) (17)
Crystallographic evidence for decomposition of dimethylformamide in the presence of ruthenium(III) chloride (2003) (17)
{Ru(CO)x}-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells (2014) (17)
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles (2016) (17)
Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro. (2011) (17)
Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands. (2009) (17)
Evidence of a metal-synergistic anion bond in thallium(III) transferrin (1988) (17)
Short-chain oligopeptides with copper(II) binding properties: The impact of specific structural modifications on the copper(II) coordination abilities. (2009) (16)
Na/K-ATPase as a target for anticancer metal based drugs: insights into molecular interactions with selected gold(iii) complexes. (2017) (16)
Interactions of selected gold(III) complexes with DNA G quadruplexes. (2015) (16)
A novel class of peptides with facilitating action on neuronal nicotinic receptors of rat chromaffin cells in vitro: functional and molecular dynamics studies. (2002) (16)
Reactions of cisplatin and cis-[PtI2(NH3)2] with molecular models of relevant protein sidechains: A comparative analysis. (2020) (16)
Induction of a Four‐Way Junction Structure in the DNA Palindromic Hexanucleotide 5′‐d(CGTACG)‐3′ by a Mononuclear Platinum Complex (2019) (16)
Coordination compounds and life processes (1992) (15)
pH-dependent properties of cobalt(II) carboxypeptidase A-inhibitor complexes. (1992) (15)
The fate of differently functionalized gold nanorods in human serum: A response from capillary electrophoresis-inductively coupled plasma mass spectrometry. (2017) (15)
Synthesis and Mode of Action Studies on Iridium(I)–NHC Anticancer Drug Candidates (2018) (15)
A 1H NMR study of the complex of cobalt(II) with 2,5,8,11-tetramethyl-2,5,8,11-tetraazadodecane in aerated aqueous solutions (1995) (15)
Anticancer Ruthenium(III) Complex KP1019 Interferes with ATP‐Dependent Ca2+ Translocation by Sarco‐Endoplasmic Reticulum Ca2+‐ATPase (SERCA) (2014) (15)
Proton NMR spectra of the Co4S11 cluster in metallothioneins: a theoretical model (1989) (15)
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. (2020) (15)
Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties (2017) (15)
Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems. (2016) (14)
Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA (2000) (14)
Spectral characterization of vanadium-transferrin systems. (1985) (14)
The metal-binding properties of ovotransferrin. An investigation of cobalt(II) derivatives. (1986) (14)
A two-dimensional NMR study of Co(II)7 rabbit liver metallothionein. (1993) (14)
Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme (2015) (13)
Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds (2021) (13)
Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole) Tetrachlororuthenate) (ICR) (2000) (13)
Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration. (2015) (13)
Tuning the interactions of PEG-coated gold nanorods with BSA and model proteins through insertion of amino or carboxylate groups. (2015) (13)
Selective interaction of ferricyanide with cluster I of Clostridium pasteurianum 2[Fe4S4] ferredoxin (1993) (13)
The leading established metal-based drugs: a revisitation of their relevant physico-chemical data (2019) (12)
Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies (2020) (12)
The pH dependent properties of metallotransferrins: a comparative study (1997) (12)
A water 17O NMR study of the pH dependent properties of superoxide dismutase. (1981) (12)
Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. (2010) (12)
Protein Metalation by Inorganic Anticancer Drugs (2020) (11)
Cobalt(II) as an NMR probe for the investigation of the coordination sites of conalbumin. (1984) (11)
Transferrin: From Inorganic Biochemistry to Medicine (1994) (11)
Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity (2008) (11)
STRUCTURE AND CYTOTOXIC PROPERTIES OF SOME SELECTED GOLD(III) COMPLEXES (1999) (11)
Nitrate as a probe of cytochrome c surface: crystallographic identification of crucial "hot spots" for protein-protein recognition. (2014) (11)
Protein interactions of dirhodium tetraacetate: a structural study. (2020) (11)
1H NMR detection of CoOH2 .dblharw. CoOH interconversions in high-spin cobalt(II) complexes (1982) (11)
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. (2015) (11)
1H-NMR investigation of the interaction of the amino terminal domain of the LexA repressor with a synthetic half-operator. (1991) (11)
Reactions of a tetranuclear Pt-thiosemicarbazone complex with model proteins. (2018) (11)
Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand. (2019) (11)
Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-Bridged Derivatives~!2009-12-08~!2010-01-15~!2010-03-25~! (2010) (10)
ESI–MS studies of the reactions of novel platinum(II) complexes containing O,O′-chelated acetylacetonate and sulfur ligands with selected model proteins (2017) (10)
New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules (2018) (10)
CD and EXAFS study of the interaction between phosvitin and copper(II) ions (1988) (10)
The combined activation of K Ca 3.1 and inhibition of K v 11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells (2017) (9)
The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose‐Derived Stem Cells, Taken as a Model (2008) (9)
A case of extensive protein platination: the reaction of lysozyme with a Pt(ii)-terpyridine complex. (2018) (9)
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles (2016) (9)
Effect of nonsynergistic anions on copper transferrin (1988) (9)
EXAFS investigation on the iron(III) binding sites of hen phosvitin (1990) (9)
Effects of chronic treatment with sodium tetrachloroaurate(III) in mice and membrane models. (2004) (9)
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones. (2011) (9)
Interaction of phosphate and pyrophosphate with cobalt(II) carboxypeptidase (1990) (9)
Inhibition of Na(+)/K(+)-ATPase and cytotoxicity of a few selected gold(III) complexes. (2014) (9)
Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. (2011) (8)
Synthesis, characterization and DNA interactions of [Pt3(TPymT)Cl3], the trinuclear platinum(II) complex of the TPymT ligand. (2018) (8)
Gold(III) Compounds as Anticancer Agents: Relevance of Gold—Protein Interactions for Their Mechanism of Action (2008) (8)
On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules (2020) (8)
New Insights into the Molecular Mechanisms of Selected Anticancer MetalCompounds through Bioinformatic Analysis of Proteomic Data (2013) (8)
Synthesis and characterisation of two new catechol-based iron(III) ion-sequestering agents (1998) (7)
cis-Pt I 2 ( NH 3 ) 2 : a Reappraisal (2015) (7)
Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin. (2015) (7)
Reaction with Proteins of a Five-Coordinate Platinum(II) Compound (2019) (7)
Potential antitumor gold drugs: DFT and XANES studies of local atomic and electronic structure (2009) (6)
EXAFS studies on the oxalate adduct of iron transferrin (1992) (6)
Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity (2021) (6)
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles (2021) (6)
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation (2018) (6)
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. (2015) (6)
Au2trien: a dinuclear gold(III) complex with unprecedented structura features. (2002) (6)
The electrochemical profiles of Auranofin and Aubipyc, two representative medicinal gold compounds: A comparative study. (2019) (6)
Frontiers in 2D NMR of paramagnetic metalloproteins (1993) (6)
Auranofin and its analogs as prospective agents for the treatment of colorectal cancer (2022) (6)
Controlling with light the interaction between trans-tetrapyridyl ruthenium complexes and an oligonucleotide. (2018) (6)
Erratum to: CE Separation and ICP-MS Detection of Gold Nanoparticles and Their Protein Conjugates (2017) (6)
Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System (2020) (6)
Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin (2019) (6)
Au2phen and Auoxo6, Two Dinuclear Oxo-Bridged Gold(III) Compounds, Induce Apoptotic Signaling in Human Ovarian A2780 Cancer Cells (2021) (6)
[Au(9-methylcaffein-8-ylidene)2 ]+ /DNA Tel23 System: Solution, Computational, and Biological Studies. (2017) (6)
Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780) (2022) (5)
1H NMR studies on lanthanides substituted transferrins. (1991) (5)
Influence of cis- and trans-diamminedichloroplatinum(II) binding on the helix-coil transition of DNAs with different GC content (1998) (5)
In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study (2021) (5)
Kinetic and structural analysis of the inactivation of urease by mixed-ligand phosphine halide Ag(I) complexes. (2021) (5)
Antiplasmodial activity of papaya leaf decoction and its synergistic effects in combination with artemisinin (2009) (5)
Diruthenium Diacetate Catalysed Aerobic Oxidation of Hydroxylamines and Improved Chemoselectivity by Immobilisation to Lysozyme (2017) (5)
The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach (2017) (5)
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. (2016) (5)
Leaf Decoction of Carica papaya Combined with Artesunate Prevents Recrudescence in Plasmodium berghei-Infected Mice (2019) (4)
NMR reveals the metabolic changes induced by auranofin in A2780 cancer cells: evidence for glutathione dysregulation. (2021) (4)
EXAFS studies of Fe(III)-phosvitin at high metal to protein ratios (1994) (4)
THALLIUM-205 AS AN NMR PROBE FOR THE INVESTIGATION OF TRANSFERRIN (1983) (4)
Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections (2014) (4)
Comparative Analysis of [Au(en)2]3+ and [Pt(en)2]2+ non Covalent Binding to Calf Thymus DNA (2000) (4)
Ytterbium(III) as a CD probe for the investigation of the metal binding sites of transferrins (1986) (4)
The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct. (2020) (4)
The reaction of artemisinin with hemin: a further insight into the mechanism (2004) (4)
Native mass spectrometry of human carbonic anhydrase I and its inhibitor complexes (2020) (4)
Antiplasmodial in vivo activity of Carica papaya leaf decoction (2010) (4)
Reactions with Proteins of Three Novel Anticancer Platinum(II) Complexes Bearing N-Heterocyclic Ligands (2021) (4)
Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study (2021) (4)
Peroxidase and superoxide dismutase activities in bean in response to ozone (1997) (4)
Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV–Vis absorption spectroscopy and ESI MS (2015) (4)
Role of aminoacidic residues inside active sites of metalloproteins (1988) (3)
Modulation of the in vitro antimalarial effects of artemisinin by selected flavonoids and by reducing agents (2007) (3)
Conjugates of Gold Nanoparticles and Antitumor Gold(III) Complexes as a Tool for Their AFM and SERS Detection in Biological Tissue (2019) (3)
EXAFS INVESTIGATIONS ON A N-TERMINAL FRAGMENT OF HUMAN TRANSFERRIN CONTAINING A SINGLE IRON BINDING SITE (1986) (3)
Medicinal Au(I) compounds targeting urease as prospective antimicrobial agents: unveiling the structural basis for enzyme inhibition. (2021) (3)
Transferrin: A Natural Carrier for Metal Ions and Drugs (1997) (3)
Modulation of the in vitro antimalarial effects of artemisinin by selected extracts: the case of olive leaf water extract (2008) (3)
The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study (2022) (3)
A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state (2008) (3)
Ruthenium-Sulfoxide Complexes with a Specific Antimetastatic Activity (1997) (2)
Selenol (-SeH) as a target for mercury and gold in biological systems: Contributions of mass spectrometry and atomic spectroscopy (2022) (2)
(S)-(+)-2-[2-(Biphenyl-2-yl)-1-methylethyl]-4,5-dihydro-1H-imidazolium hydrogen oxalate (2005) (2)
Cobalt(II) as a probe of the metal binding sites of transferrins (1990) (2)
Systems Biology of the Proteomic Analysis of Cytotoxic Gold Compounds in A2780 Ovarian Cancer Cell Line: A Network Analysis (2016) (2)
1H NMR studies on reduced high potential iron protein (HIPIP) from Chromatium Vinosum (1993) (2)
Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation (2015) (2)
EXAFS studies on copper transferrin (1992) (2)
Platinum-Based Anticancer Drugs: Unveiling Novel Mechanisms of Action of Conventional Metallodrugs for Improved Therapies. (2021) (2)
Cyclodextrin Inclusion Complexes of Auranofin and Its Iodido Analog: A Chemical and Biological Study (2021) (2)
Ruthenium(II) 1,4,7-trithiacyclononane complexes of curcumin and bisdemethoxycurcumin: Synthesis, characterization, and biological activity. (2021) (2)
Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-BridgedDerivatives (2010) (2)
Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent. (2022) (2)
Rapid and efficient purification of hypericin and pseudohypericin and inhibition of thioredoxin reductase (2009) (2)
Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. (2022) (1)
Interplay of crystallography, Raman microspectroscopy and electrospray mass spectrometry for studying the reaction between ruthenium complexes and proteins (2014) (1)
Correction to: Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin (2019) (1)
Chemical Modification of Auranofin Yields a New Family of Anticancer Drug Candidates: The Gold(I) Phosphite Analogues (2023) (1)
A 1H NMR study of cobalt(II) arsanilazocarboxypeptidase A. (1989) (1)
Large Protein Assemblies for High-Relaxivity Contrast Agents: The Case of Gadolinium-Labeled Asparaginase (2022) (1)
Evaluation of Auranofin Loading within Ferritin Nanocages (2022) (1)
New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules (2018) (1)
Direct detection of iron clusters in L ferritins through ESI-MS experiments. (2021) (1)
Correction to Promising in Vitro anti-Alzheimer Propertiesfor a Ruthenium(III) Complex (2013) (1)
Recent trends in antitumor gold(III) complexes : Innovative cytotoxic metallodrugs for cancer treatment (2005) (1)
Comparative reactivity of medicinal gold(I) compounds with the cyclic peptide vasopressin and its diselenide analogue. (2021) (1)
Time course of antioxidant enzymes in the paraquat-resistant and tolerant Heary fleabane (Conyza bonariensis) biotypes in response to ozone exposure and paraquat application (2019) (1)
Computationally enhanced X-ray diffraction analysis of a gold(III) complex interacting with the human telomeric DNA G-quadruplex. Unravelling non-unique ligand positioning. (2022) (1)
Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study (2022) (1)
X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme (2007) (0)
The Metal-binding Properties of Ovotransferrin (2001) (0)
Reactivity of CORM [RuII(CO)3Cl2{N-(N1-methylbenzimidazole)}] with aminoacids. Synthesis, and analytical and structural study for the new binuclear cis-[RuI(CO)2(N-MBI)(μ2-O,O-BAL)]2 sawhorse complex at solid state and in solution (2019) (0)
The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach (2017) (0)
Bottom-up mass spectrometry proteomics strategies for the identification of metallodrug binding sites on proteins: the search for a general protocol to assess adduct stability (2015) (0)
Reactions of proteins with a few organopalladium compounds of medicinal interest (2022) (0)
Antitumor gold(III) complexes (2005) (0)
Ferritin-based anticancer metallodrug delivery: Encapsulation of Arsenoplatin-1 within the ferritin nanocage (2020) (0)
Frontispiece: Protein Metalation by Anticancer Metallodrugs: A Joint ESI MS and XRD Investigative Strategy (2017) (0)
Mono- and Binuclear Gold Based Complexes with Anti-tumoral Properties (2012) (0)
Synergistic antiplasmodial activity of artemisinin and olive leaf decoction: the role of the constituents of the phytocomplex (2009) (0)
2D 1H NMR investigations of paramagnetic proteins: The oxidized form of ferredoxin from clostridium pasteurianum. (1991) (0)
Erratum: Leaf Decoction of Carica papaya Combined with Artesunate Prevents Recrudescence in Plasmodium berghei-Infected Mice (2019) (0)
Gold complexes as potential antimalarial agents (2012) (0)
Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV–Vis absorption spectroscopy and ESI MS (2015) (0)
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme (2012) (0)
The Dependence of the Copper Dissociation Rate Constants from Human(Serum)- and Ονο-Transferrin on pH and the Anions (1999) (0)
Xray structure of cisplatin-protein interactions: selective platination of his 19 in superoxide dismutase (2006) (0)
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents (2017) (0)
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles (2016) (0)
Proton NMR and NOE studies on the cobalt(II) derivative of rabbit metallothionein (1989) (0)
Synthesis and structural characterization of new mono and dinuclear gold(I) complexes as potential antitumor agents (2010) (0)
New gold carbene complexes as candidate anticancer agents (2016) (0)
Mass Spectrometry and Metallomics: binding site location in the Cyt c-CDDP model system (2017) (0)
Biological studies on a new class of gold complexes with pyridinyl-benzoimidazole (2010) (0)
Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles (2016) (0)
Exploring metal complexes-protein/peptide interactions by high resolution mass spectrometry (2009) (0)
X-ray structure of the adduct formed between hen egg white lysozyme and NAMI-A (2014) (0)
Exploring the interactions between phosphane-based platinum(II) dichlorides and cytochrome c by electrospray ionization high resolution mass spectrometry (2011) (0)
Solution structure of a human G-Quadruplex hybrid-2 form in complex with a Gold-ligand. (2017) (0)
Superoxide dismutase and peroxidase activities in bean leaves folowing acute ozone stress (1996) (0)
X-ray Structure of the Adduct formed between cisplatin and Ribonuclease A (2014) (0)
ESI–MS studies of the reactions of novel platinum(II) complexes containing O,O′-chelated acetylacetonate and sulfur ligands with selected model proteins (2017) (0)
An EXAFS study on the interaction between serum transferrin and oxalate as synergistic anion (1989) (0)
The crystal structure of a NAMI A-Carbonic Anhydrase II adduct discloses the mode of action of this novel anticancer metallodrug (2011) (0)
First Crystal Structure for an Oxaliplatin-Protein Complex (2015) (0)
Supporting Information Crystal X-ray Structure for the Complex formed in the Reaction between Oxaliplatin and Lysozyme (2014) (0)
Correction: Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(ii) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. (2018) (0)
Xray structure of cisplatin-protein interactions (2006) (0)
Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation (2015) (0)
Mass spectrometry and metallomics: stability and binding site location in the Cyt c-CDDP model system (2016) (0)
CCDC 193259: Experimental Crystal Structure Determination (2002) (0)
Coordination Modes of Histidine. Part 10. Iron(III) Tyrosinate Models. Synthesis and Spectroscopic and Stereochemical Studies of Iron(III) Complexes of N-Salicylidene-L-amino Acids. (1987) (0)
Gold-Based Metal Drugs as Inhibitors of Coronavirus Proteins: The Inhibition of SARS-CoV-2 Main Protease by Auranofin and Its Analogs (2022) (0)
Synthesis, structural characterization and in vitro cytotoxicity of gold complexes with 2-(2-pyridyl)benzimidazole. Gold(III) vs. Gold(I), mononuclear vs. binuclear derivatives (2011) (0)
Crystal structure of cisplatinated bovine Cu,Zn superoxide dismutase (2006) (0)
Studies of cytotoxic gold compounds: interactions with model proteins and with the copper chaperone Atox-1 (2012) (0)
A biophysical study of the interactions of palladium(II), platinum(II) and gold(III) complexes of aminopyridyl-2,2'-bipyridine ligands with RNAs and other nucleic acid structures. (2022) (0)
Novel gold(I)/gold(III) compounds bearing saccharinate ligands: structural and solution chemistry, protein binding behaviour and antiproliferative effects (2009) (0)
XAS/XRD complementary data on metallodrugs and their proteins complexes (2011) (0)
Structure of the complex of a human telomeric DNA with Au(caffein-2-ylidene)2 (2016) (0)
CCDC 753959: Experimental Crystal Structure Determination (2011) (0)
Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme (2015) (0)
Interaction of the antitumour ruthenium(III) complex trans-indazolium[tetrachlorobisindazoleruthenate(III)] with apotransferrin (1993) (0)
Reviewers of the Journal of Chemotherapy (2010) (0)
Catalytic and Biological studies of Au(III) complexes with pyridinyl-oxazoline ligands (2010) (0)
Triethylphosphine gold iodide (I), the iodido analogue of Auranofin: comparative studies of a potential antineoplastic agent (2016) (0)
A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition (2011) (0)
Jacobs Journal of Bioinformatics and Proteomics Systems Biology of the Proteomic Analysis of Cytotoxic Gold Compounds in A 2780 Ovarian Cancer Cell Line : A Network Analysis (2016) (0)
Electron transfer complexes: Experimental mapping of the redox-dependent cytochrome c electrostatic surface (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luigi Messori?

Luigi Messori is affiliated with the following schools:

University of Florence
University of Bologna